Home Companies Catalysts Deep Dives
Veozah fezolinetant APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOther
Launch2023-05-12
US LOE2036-05-01
Peak Sales Est$1500M
Formulations[{"id":"veozah-tablet","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary":t
Companies
ALPMY (ORIGINATOR)100%
Mechanism: NK3 receptor antagonist
Expert: Neurokinin 3 receptor antagonist normalizing KNDy neuron activity for VMS.
Everyday: Blocks brain signals that cause hot flashes during menopause.
Targets: ["NK3R"]
Revenue History
PeriodRevenue ($M)
FY2024$225M
H1 FY2025$153M
Programs (1)
IndicationStageKey StudyRegional Status
Vasomotor symptomsAPPROVEDSKYLIGHT[{"stage":"APPROVED","region":"US","approval_date":"2023-05-12"}]
Upcoming Catalysts (1)
Veozah - Commercial Uptake Updates 2026
Notes
Non-hormonal menopause VMS treatment. First NK3R antagonist approved. Ex-US as Veoza.
Data from Supabase · Updated 2026-03-24